$INSM

Flammer Martina M.D. sold $1.4M of INSM

Flammer Martina M.D. (Chief Medical Officer) sold 12,302 shares of INSMED Inc (INSM) at an average of $109.98 ($109.02–$110.60, $1.35M total) across 2 trades on 2026-07-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Flammer Martina M.D.
Published Jul 8, 2026, 8:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 8, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$INSM
Neutral
high confidence
Mentioned
$INSM
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INSMNeutralLow
01

Why it matters

The newest fact is the CMO’s open-market sale size, price range, and post-transaction holdings, with explicit 10b5-1 plan context.

02

Market read

This provides a fresh, auditable datapoint on insider selling activity, but it does not introduce new company fundamentals.

03

What to watch

Traders may over-weight insider sales; without accompanying buy transactions, guidance, or business updates, the signal is mostly sentiment-level.

Relevance 5/10Novelty 3/10Timing: Filed on 2026-07-08 after the 2026-07-06 sale execution.

Background

The article is an SEC Form 4 insider transaction disclosure for INSMED Inc.

Company-level read

Ticker impact

$INSMNeutralHigh confidence
Context

INSMED CMO Flammer Martina sold about 12,302 shares in open-market transactions totaling about $1.35M under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

The filing is a Form 4 insider sale with stated 10b5-1 pre-arranged plan, and it provides no new operational, financial, or regulatory information beyond the transaction details.

Market effects

No sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • INSMED Inc

    Company whose insider transaction is disclosed on SEC Form 4.

  • Flammer Martina M.D.

    Chief Medical Officer who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$INSMMed

Brensocatib Launches in Japan for Non-CF Bronchiectasis

Insmed Inc. launched Brinsupri (brensocatib hydrate) in Japan for non-cystic fibrosis bronchiectasis, following approvals in the U.S. and Europe. The treatment, backed by clinical trial data, is the first of its kind in Japan. Insmed executives highlighted its potential to address unmet medical needs and improve patient outcomes.

$INSMHigh

Insmed launches bronchiectasis treatment in Japan

Insmed Incorporated (INSM) launched BRINSUPRI Tablets 25 mg in Japan for treating non-cystic fibrosis bronchiectasis in adults and pediatric patients 12+. The therapy, approved in August 2026, is the first of its kind in Japan. BRINSUPRI is also approved in the U.S. and EU for similar indications. Common side effects include rash, dry skin, and hypertension. Insmed is a biopharmaceutical company based in New Jersey.

$INSMMed

In Japan, patients can now get the only approved treatment for a lung disease that permanently widens airways.

Insmed Inc. announced that BRINSUPRI, the first approved treatment for non-cystic fibrosis bronchiectasis (NCFB), is now available by prescription in Japan. BRINSUPRI is a once-daily oral therapy designed to reduce airway inflammation. The company highlighted the substantial disease burden of NCFB and the need for effective treatments. Insmed also provided details on the drug's safety profile and potential side effects, including dermatologic and gingival adverse reactions.

$INSMMedAI 8/10

Insmed launches four phase 3 trials for lung disease therapy

Insmed Inc. (INSM) launched four Phase 3 trials for its lung disease therapy, treprostinil palmitil. The PALM program includes studies for pulmonary arterial hypertension, pulmonary hypertension with interstitial lung disease, progressive pulmonary fibrosis, and idiopathic pulmonary fibrosis. Three trials have started, with the fourth expected in early 2027. The therapy is not yet approved.